Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 2Recurrence 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

fludarabine phosphate 34Cyclophosphamide 31Peripheral Blood Stem Cell Transplantation 27Mycophenolic Acid 25Cyclosporine 23Antilymphocyte Serum 23Busulfan 20Tacrolimus 17Radiotherapy 17Filgrastim 17Whole-Body Irradiation 15Methotrexate 15Methylprednisolone 14Melphalan 13Cord Blood Stem Cell Transplantation 12venetoclax 9Cytarabine 8Azacitidine 8fludarabine 5Etoposide 5sargramostim 4Therapeutics 4Sirolimus 4Decitabine 4Clofarabine 4Alemtuzumab 4thymoglobulin 3nilotinib 3merphos 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × CYC065 × Myeloid × Clear all
NCT04017546 2024-09-19

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

Cyclacel Pharmaceuticals, Inc.

Phase 1 Completed
14 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡